Abstract: Described are methods for treating a patient with a therapeutic drug using a combination of genetic and non-genetic information to tailor the dose of the drug to the patient.

Abstract: Described are methods for treating a patient with a therapeutic drug using a combination of genetic and non-genetic information to tailor the dose of the drug to the patient.

Abstract: The invention provides systems and methods for producing a ranked list of drugs for administration to a patient in need thereof, the ranked list produced by calculating for each drug a score that is the product of a patient vector, a weighting vector, and the drug's column value in a disease matrix.

Abstract: The invention provides systems and methods for producing a ranked list of drugs for administration to a patient in need thereof, the ranked list produced by calculating for each drug a score that is the product of a patient vector, a weighting vector, and the drug's column value in a disease matrix.

Abstract: The invention provides population models, methods, and algorithms for targeting a dosing regimen or compound selection to an individual patient. The methods and algorithms of the invention utilize population models that incorporate genotype information for genes encoding drug metabolizing enzymes for one or more compounds of interest. The methods allow integration of genotype information for one or more genes encoding a drug metabolizing enzyme, particularly a cytochrome P450 gene with patient data. The methods allow integration of genotype information and the effect of one or more compounds on one or more drug metabolizing enzymes. The methods allow iterative feedback of drug metabolizing data obtained from a patient into the process of generating a dosage regimen recommendation for a compound of interest for an individual patient.

Abstract: The methods and compositions of the invention find use in the clinical diagnosis of primary immunodeficiencies, particularly Wiskott-Aldrich related syndromes. The compositions of the invention include isolated nucleic acid molecules and oligonucleotide pairs suitable for use in amplifying regions of the Wiskott-Aldrich syndrome protein gene and in determining the nucleotide sequence of the Wiskott-Aldrich syndrome protein gene in a patient. The invention facilitates efficient, cost-effective amplification of one or more regions of the Wiskott-Aldrich syndrome protein gene. The nucleotide sequence of amplified DNA comprising one or more regions of the Wiskott-Aldrich Syndrome Protein gene can be determined using the methods and compositions of the invention. Knowledge of the patient's nucleotide sequence in the Wiskott-Aldrich Syndrome Protein gene allows diagnosis of the patient's primary immunodeficiency.

Abstract: The invention provides population models, methods, and algorithms for targeting a dosing regimen or compound selection to an individual patient. The methods and algorithms of the invention utilize population models that incorporate genotype information for genes encoding drug metabolizing enzymes for one or more compounds of interest. The methods allow integration of genotype information for one or more genes encoding a drug metabolizing enzyme, particularly a cytochrome P450 gene with patient data. The methods allow integration of genotype information and the effect of one or more compounds on one or more drug metabolizing enzymes. The methods allow iterative feedback of drug metabolizing data obtained from a patient into the process of generating a dosage regimen recommendation for a compound of interest for an individual patient.

Abstract: The methods and compositions of the invention find use in the clinical diagnosis of TNFRSF6-related syndromes, particularly autoimmune lymphoproliferative syndrome (ALPS). The compositions of the invention include isolated nucleic acid molecules and oligonucleotide pairs suitable for use in amplifying regions of the TNFRSF6 gene and in determining the nucleotide sequence of the TNFRSF6 gene in a patient. The invention facilitates efficient, cost-effective amplification of one or more regions of the TNFRSF6 gene. The nucleotide sequence of amplified DNA comprising one or more regions of the TNFRSF6 gene can be determined. Knowledge of the patient's nucleotide sequence in the TNFRSF6 gene allows diagnosis of the patient.

Abstract: The present invention is related to diagnostic arrays comprising primers for various regions of candidate genes involved in hearing loss, specifically pediatric hearing loss. The invention further is directed to methods for diagnosing a cause or risk factor for hearing loss. In some embodiments, these methods include obtaining a sample from a patient; screening the sample for the presence or absence of alleles of at least 5 loci associated with a risk for hearing loss to obtain a result of the screening; and making a diagnosis based upon the result.